Cost–effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis

Written by Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F

Aim: To compare the cost–effectiveness of different disease-modifying therapies’ strategies for treatment of relapsing-remitting multiple sclerosis. Methods: A Markov model was developed to assess the cost–effectiveness and incremental cost–effectiveness ratios for different strategies of using disease-modifying therapies from a US third-party payer perspective. All costs were converted to 2014 US$. Results: Over 20 years, the total costs per patient were estimated at US$161,136.60 for Strategy 1 (symptom management [SM] alone), US$551,650.66 for Strategy 2 (SM and IFN-β-1a), US$703,463.60 for Strategy 3 (SM and natalizumab) and US$670,985.24 for Strategy 4 (SM and alemtuzumab). The accumulated quality-adjusted life years were 10.49, 10.66,...

To view this content, please register now for access

It's completely free